CN1352553A - Weight loss after pregnancy - Google Patents
Weight loss after pregnancy Download PDFInfo
- Publication number
- CN1352553A CN1352553A CN00807535A CN00807535A CN1352553A CN 1352553 A CN1352553 A CN 1352553A CN 00807535 A CN00807535 A CN 00807535A CN 00807535 A CN00807535 A CN 00807535A CN 1352553 A CN1352553 A CN 1352553A
- Authority
- CN
- China
- Prior art keywords
- chemical compound
- formula
- cyclobutyl
- chlorphenyl
- require
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035935 pregnancy Effects 0.000 title claims abstract description 5
- 230000004580 weight loss Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 71
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 5
- 150000004682 monohydrates Chemical class 0.000 claims abstract description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 27
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 10
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 claims description 7
- 210000000577 adipose tissue Anatomy 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 description 10
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 238000001802 infusion Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000000407 monoamine reuptake Effects 0.000 description 4
- 229960004425 sibutramine Drugs 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000012053 oil suspension Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229960003914 desipramine Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 238000001030 gas--liquid chromatography Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000004460 liquid liquid chromatography Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- SFLSHLFXELFNJZ-CMIMLBRMSA-N 4-[(1r)-2-amino-1-hydroxy-1-tritioethyl]benzene-1,2-diol Chemical compound NC[C@@](O)([3H])C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-CMIMLBRMSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010021030 Hypomania Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A compound of formula (I) or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N - dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for aiding weight loss after pregnancy.
Description
The present invention relates to a kind of conceived back ways of preventing obesity that helps.
According to the present invention, a kind of conceived back ways of preventing obesity that helps is provided, a kind of formula I chemical compound for the treatment of effective dose of the people who needs in the method comprises its enantiomer and its pharmaceutically acceptable salt, and pharmaceutically acceptable diluent or carrier,
R wherein
1And R
2Independent is H or methyl.
The preferred compound of formula I is N, N-dimethyl-1-[1-(4-chlorphenyl) cyclobutyl]-3-methylbutylamine or its salt, for example hydrochlorate.A form slection formula of this hydrochlorate is its monohydrate.
Formula I chemical compound such as N, N-dimethyl-1-[1-(4-chlorphenyl) cyclobutyl]-3-methylbutylamine, N-{1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methyl butyl }-N-methylamine and 1-[1-(4-chlorphenyl) cyclobutyl]-preparation of 3-methylbutylamine and salt thereof preparation and the purposes in the depressed medicine of treatment be described in british patent specification 2098602 and United States Patent (USP) 4, in 522,328.Formula I chemical compound such as N, N-dimethyl-1-[1-(4-chlorphenyl) cyclobutyl]-3-methylbutylamine and the purposes of salt in the treatment parkinson thereof be described among the disclosed PCT application WO 88/06444.N, N-dimethyl-1-[1-(4-chlorphenyl) cyclobutyl]-3-methylbutylamine and the purposes of salt in treatment brain function disease thereof be described in United States Patent (USP) 4,939, in 175.N, N-dimethyl-1-[1-(4-chlorphenyl) cyclobutyl]-purposes of 3-3-methyl butylamine hydrochloride in the treatment obesity be described among the disclosed PCT application WO90/06110.A special preferred form of this chemical compound is N, N-dimethyl-1-[1-(4-chlorphenyl) cyclobutyl]-3-3-methyl butylamine hydrochloride monohydrate (sibutramine hydrochlorate), it is described in the european patent number 230742.N, N-dimethyl-1-[1-(4-chlorphenyl) cyclobutyl]-3-methylbutylamine and salt thereof is described among the disclosed PCT application WO95/20949 in the purposes that improvement has in the people of damaged glucose tolerance or non-insulin-dependent diabetes mellitus patient's the glucose tolerance.
It should be appreciated by those skilled in the art that formula I chemical compound contains a chiral centre.When formula I chemical compound contained a single chiral centre, can there be two enantiomeric forms in it.The present invention includes and use the independent enantiomer or the mixture of enantiomer.Can resolve enantiomer by method known to those skilled in the art, for example forming can isolating diastereo-isomerism salt or complex, as separating by crystallization; Can isolating diastereo-isomerism derivant by forming, as separating by crystallization, gas-liquid chromatography or liquid chromatography; The selective reaction of a kind of enantiomer and enantiotopic special reagent, for example oxydasis or reduction reaction are separated enantiomer that modify or unmodified subsequently; Or in chiral environment, separate by gas-liquid chromatography or liquid chromatography, as on the chiral support as have the silica gel of a bonded chiral ligand or in the presence of chiral solvent, separate.Should be understood that with a kind of in the above-mentioned separation method needed enantiomer is converted into another chemical entities, next step requirement discharges needed enantiomerism form.Perhaps,, use optional active agent, substrate, catalyst or solvent can synthesize specific enantiomer, or an enantiomer is converted into the synthetic specific enantiomer of another enantiomer by asymmetric transformation by asymmetric synthesis.
The preferred compound of formula I is N, N-dimethyl-1-[1-(4-chlorphenyl) cyclobutyl]-3-methylbutylamine, N-{1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methyl butyl }-N-methyl amine and 1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methylbutylamine, comprise their racemic modification, independent enantiomer and mixture, and pharmaceutically acceptable salt.
Can the synthetic method by enantio-selectivity prepare independent enantiomer by optional active precursor, or by resolve can the as described above preparation racemic compound prepare independent enantiomer.The enantiomer of the secondary amine of formula I also can prepare by the following method, the racemic modification that at first prepares corresponding primary amines, the latter is resolved to independent enantiomer, with the method that is described in british patent specification 2098602 optically pure primary amine enantiomer is converted into required secondary amine then.
The instantiation of formula I chemical compound is: (+)-N-{1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methyl butyl }-the N-methyl amine; (-)-N-{1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methyl butyl }-the N-methyl amine; (+)-1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methylbutylamine; (-)-1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methylbutylamine; (+)-N-{1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methyl butyl }-N, the N-dimethyl amine; (-)-N-{1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methyl butyl }-N, the N-dimethyl amine.
Preferred salt hydrochlorate all in each case, but free alkali and other pharmaceutically acceptable salt also suit.
Can be with any known pharmaceutical dosage form giving construction I chemical compound.The amount of institute's administered compound will depend on many factors, comprise patient's age, severity of disease and the medical history in patient's past, and the amount of institute's administered compound is always in attending doctor's reasonable power to make decision scope, but general designing institute gives the dosage of chemical compound in every day 0.1 to 50mg, preferred 1 in the scope of 30mg, can be in single or divided doses.
The known pharmaceutical dosage form that the preferred composition that peroral dosage form uses for the present invention and these dosage forms are this type of administering mode, for example tablet, capsule, granule, syrup and water or oil suspension.The excipient that the excipient that uses when these compositionss of preparation is familiar with as the pharmacists field.Can from reactive compound with as the filler of calcium phosphate, as the disintegrating agent of corn starch, as the lubricant of magnesium stearate, prepare tablet as the binding agent of microcrystalline Cellulose or polyvinylpyrrolidone and the mixture of other optional member known in the art, as this mixture being suppressed in blocks by known method.If desired, can be with known method and excipient with described tablet coating, described coating can comprise the enteric coating that for example uses hydroxypropyl methylcellulose phthalate.Can prepare tablet so that discharge chemical compound of the present invention constantly with method known to those skilled in the art.If desired, can enteric coating be provided for this type of tablet, as passing through to use the Cellulose Acetate Phthalate coating with known method.Similarly, can contain the capsule of reactive compound (being added with or not being added with excipient) with the preparation of known method, for example hard or Perle and, if desired, can provide enteric coating with known method.Can prepare capsular content so that discharge reactive compound constantly with known method.Every or every routine of tablet and capsule contains 1 to 50mg.
For example, the dosage form of other oral administration is included under the existence of avirulent suspending agent such as sodium carboxymethyl cellulose, contains the waterborne suspension of reactive compound and contains the oil suspension of The compounds of this invention in moisture media in suitable vegetable oil such as Oleum Arachidis hypogaeae semen.Can and or not be mixed with granule with described reactive compound with the excipient that adds.The patient can directly take in this granule or before absorption it be joined in the appropriate liquid carrier (as water).Described granule can contain disintegrating agent, and for example the effervescent conjugates (effervescent couple) that is formed by a kind of acid and a kind of carbonate or bicarbonate is to so that promote dispersion in liquid media.
Curative formula I reactive compound preparation a kind of patient can be become and the compositions in the oral cavity can be retained in so that the through port transmucosal gives this reactive compound.
The dosage form of suitable rectally is the known pharmaceutical dosage form of this type of administering mode, as contains the suppository of cocoa butter or Polyethylene Glycol substrate.
The dosage form of suitable parenteral is the known pharmaceutical dosage form of this type of administering mode, as sterile suspensions in suitable solvent or sterile solution.
The dosage form of suitable topical can comprise a kind of substrate, for the described chemical compound of transdermal administration, medicinal activity compound of the present invention is dispersed in the substrate so that this chemical compound keeps and contact skin.Can mix with reactive compound and a kind of local vehicle such as mineral oil, vaseline and/or a kind of wax such as paraffin or Cera Flava by messenger drug, prepare suitable transdermal composition with a kind of effective percutaneous penetration enhancer such as dimethyl sulfoxide or propylene glycol.Perhaps, this reactive compound can be dispersed in pharmaceutically acceptable emulsifiable paste, gel or the ointment base.The amount of the reactive compound that contains in topical formulations should be intended to this topical formulations is used for the treatment effective dose of the chemical compound that can transmit during the skin.
Can with formula I therapeutical active compound be formulated as a kind of compositions of disperseing to enter into patient oral cavity or nasal cavity as aerosol.This type of aerosol can or contain the compression wrap administration of volatile propellant by a kind of pump pressure bag.
The formula I therapeutical active compound that is used for the inventive method also can be by continuing the infusion administration from an external source, as by intravenous infusion administration or be placed on intravital chemical compound source from one and continue medication.Implant the bank contain chemical compound that will infusion endogenous comprising, for example this chemical compound can continue to discharge by infiltration, and for the chemical compound of infusion, implant can for (a) liquid as treating a kind of oil suspension of infusion chemical compound, a kind ofly be difficult to water-soluble derivant such as dodecanoate or lipophile ester or (b) to implant the solid that carrier format exists, as synthetic resin or ceroidlike material.Described carrier can contain the entity of part chemical compound to be passed for the single entities (single body) that contains all chemical compounds or for a series of several.The amount of the reactive compound that exists in endogenous should be able to discharge the chemical compound of treatment effective dose in long-time.
In some preparation, it may be useful using chemical compound of the present invention with the particulate form of very little particle diameter, for example uses the microgranule that obtains by fluid energy mill.
In compositions of the present invention, if desired, this reactive compound can make up with other adaptive medicinal active ingredient.
In addition, the invention provides formula I chemical compound and help purposes in the medicine of conceived back fat-reducing in production.
On the other hand, the present invention further provides a kind of Pharmaceutical composition that helps the fat-reducing of conceived back, said composition comprises formula I chemical compound and pharmaceutically acceptable diluent or carrier.
Pregnancy can cause too much increase of body weight and maintenance.It is desirable that phenolics increases a certain amount of body weight.The weight increase that has exceeded desired quantity mainly is mother's a fatty tissue.These fatty tissuees are responsible for the body weight that the phenolics that keeps puerperal increases to a great extent just.This keeps the reflection energy balance in puerperal, and this energy balance can not cause the catabolism of the fatty tissue that increased.Giving construction I chemical compound can help to change the described energy balance.
Monoamine re-uptake inhibitor is used for the treatment of some disease that the present invention describes always., known that these chemical compounds have many shortcomings.At first, this compounds is not effective to all patients.Secondly, compounds effective can not be treated disease completely.The 3rd, the chemical compound of the type is known many disadvantageous side effect.That this type of side effect comprises is nauseating, sexual dysfunction, slight headache (headedness), drowsiness, night sweat, vibration, xerostomia, weak, insomnia, diarrhoea, headache, vomiting, anxiety, drowsiness, giddy, fever, erythra or anaphylaxis, arthralgia, myalgia, spasm, hypomania and manic.
Sibutramine (formula I, R
1=CH
3, R
2=CH
3) having a pharmacological profile figure, this scattergram is unique in monoamine re-uptake inhibitor.Its pharmacological activity metabolite, (metabolite 1, R in formula I
1=H, R
2=CH
3With metabolite 2, R in formula I
1=H, R
2=H) sibutramine suppresses the reuptake of all three monoamines, these 3 kinds of amine are different from 5-hydroxy tryptamine (5-HT) selectivity reuptake inhibitor such as fluoxetine, the reuptake inhibitor of norepinephrine selectivity such as desmethylimipramine, the reuptake inhibitor of dopamine selectivity such as BUP, and 5-hydroxy tryptamine-NRI such as venlafaxine (table 1).The associating of the pharmacological action that this value of being is unique, this synergy make sibutramine and other formula I chemical compound help the fat-reducing of conceived back effectively.
Carry out following analysis with the method that is similar to the WO98/41528 description.
Table
Embodiment 1 and 2 and the monoamine re-uptake inhibitor of the various references external monoamine-reuptake in rat cerebral tissue suppress to distribute relatively
Described result is 〉=3 meansigma methodss of measuring separately.Embodiment 1: R in formula I
1=H, R
2=CH
3Embodiment 2: R in formula I
1=H, R
2=H
Ki(nM) | |||
[ 3H] norepinephrine | [ 3H]5-HT | [ 3H] dopamine | |
Embodiment 1 | 3 | ?18 | ?24 |
Embodiment 2 | 5 | ?26 | ?31 |
BUP | 2590 | ?18312 | ?409 |
Desmethylimipramine | 2 | ?200 | ?4853 |
Fluoxetine | 320 | ?11 | ?2025 |
Venlafaxine | 196 | ?26 | ?2594 |
The effect of formula I chemical compound in treatment body weight in puerperal keeps can confirm by the clinical trial of setting up in relevant crowd.
With various specific embodiments the present invention has been described., can carry out many changes and modification and still maintain in the scope and spirit of the present invention.
Claims (20)
1. one kind helps the ways of preventing obesity in puerperal, and this method comprises the formula I chemical compound of the human therapy effective dose that needs, and comprises its enantiomer and its pharmaceutically acceptable salt, and pharmaceutically acceptable diluent or carrier,
R wherein
1And R
2Independent is H or methyl.
2. the method that requires of claim 1, wherein said fat-reducing in puerperal is relevant with mother's fatty tissue.
3. the methods that require of claim 1 or 2, wherein said formula I chemical compound is N, N-dimethyl-1-[1-(4-chlorphenyl) cyclobutyl]-the 3-3-methyl butylamine hydrochloride.
4. the methods that require of claim 1 or 2, wherein said formula I chemical compound is the N of monohydrate form, N-dimethyl-1-[1-(4-chlorphenyl) cyclobutyl]-the 3-3-methyl butylamine hydrochloride.
5. the methods that require of claim 1 or 2, wherein said formula I chemical compound is (+)-N-[1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methyl butyl]-the N-methylamine.
6. the methods that require of claim 1 or 2, wherein said formula I chemical compound is (-)-N-{1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methyl butyl }-the N-methyl amine.
7. the methods that require of claim 1 or 2, wherein said formula I chemical compound is (+)-1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methylbutylamine.
8. the methods that require of claim 1 or 2, wherein said formula I chemical compound is (-)-1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methylbutylamine.
9. the methods that require of claim 1 or 2, wherein said formula I chemical compound is (+)-N-{1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methyl butyl }-N, N dimethylamine.
10. the methods that require of claim 1 or 2, wherein said formula I chemical compound is (-)-N-{1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methyl butyl }-N, N dimethylamine.
11. claim 1 or 2 methods that require, wherein said formula I chemical compound is (±)-N-{1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methyl butyl }-the N-methylamine.
12. claim 1 or 2 methods that require, its Chinese style I chemical compound is (±)-1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methylbutylamine.
13. claim 1 or 2 methods that require, its Chinese style I chemical compound is (±)-N-{1-[1-(4-chlorphenyl) cyclobutyl]-the 3-methyl butyl }-N, N dimethylamine.
14. formula I chemical compound comprises its enantiomer and its pharmaceutically acceptable salt, the purposes in producing the medicine that helps pregnancy-related fat-reducing in puerperal,
R wherein
1And R
2Independent is H or methyl.
15. the purposes that claim 14 requires, wherein said weight increase is relevant with mother's fatty tissue.
16. claim 14 or 15 purposes that require, wherein said formula I chemical compound is N, N-dimethyl-1-[1-(4-chlorphenyl) cyclobutyl]-the 3-3-methyl butylamine hydrochloride.
17. claim 14 or 15 purposes that require, wherein said formula I chemical compound is N, N-dimethyl-1-[1-(4-chlorphenyl) cyclobutyl]-3-3-methyl butylamine hydrochloride monohydrate.
18. a Pharmaceutical composition that is used to help the fat-reducing in puerperal, said composition comprises a kind of formula I chemical compound for the treatment of effective dose, comprises its enantiomer and its pharmaceutically acceptable salt, and pharmaceutically acceptable diluent or carrier,
R wherein
1And R
2Independent is H or methyl.
19. the Pharmaceutical composition that claim 18 requires, wherein said formula I chemical compound is N, N-dimethyl-1-[1-(4-chlorphenyl) cyclobutyl]-the 3-3-methyl butylamine hydrochloride.
20. the Pharmaceutical composition that claim 18 requires, wherein said formula I chemical compound is N, N-dimethyl-1-[1-(4-chlorphenyl) cyclobutyl]-monohydrate of 3-3-methyl butylamine hydrochloride.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12514999P | 1999-03-19 | 1999-03-19 | |
US60/125149 | 1999-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1352553A true CN1352553A (en) | 2002-06-05 |
Family
ID=22418407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN00807535A Pending CN1352553A (en) | 1999-03-19 | 2000-03-17 | Weight loss after pregnancy |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1162966A4 (en) |
JP (1) | JP2002539253A (en) |
KR (1) | KR20010113848A (en) |
CN (1) | CN1352553A (en) |
AU (1) | AU4172900A (en) |
BG (1) | BG105995A (en) |
BR (1) | BR0009078A (en) |
CA (1) | CA2367268A1 (en) |
CZ (1) | CZ20013282A3 (en) |
HU (1) | HUP0200500A2 (en) |
IL (1) | IL145243A0 (en) |
MX (1) | MXPA01009465A (en) |
NO (1) | NO20014474L (en) |
NZ (1) | NZ514015A (en) |
PL (1) | PL351080A1 (en) |
SK (1) | SK13362001A3 (en) |
TR (1) | TR200102694T2 (en) |
WO (1) | WO2000056317A1 (en) |
ZA (1) | ZA200107680B (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE61928B1 (en) * | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
DE19518988A1 (en) * | 1995-05-29 | 1996-12-05 | Basf Ag | Use of aryl substituted cyclobutylalkylamines to treat obesity |
-
2000
- 2000-03-17 SK SK1336-2001A patent/SK13362001A3/en unknown
- 2000-03-17 PL PL00351080A patent/PL351080A1/en not_active Application Discontinuation
- 2000-03-17 NZ NZ514015A patent/NZ514015A/en not_active Application Discontinuation
- 2000-03-17 HU HU0200500A patent/HUP0200500A2/en unknown
- 2000-03-17 BR BR0009078-6A patent/BR0009078A/en not_active Application Discontinuation
- 2000-03-17 JP JP2000606222A patent/JP2002539253A/en not_active Withdrawn
- 2000-03-17 EP EP00921401A patent/EP1162966A4/en not_active Withdrawn
- 2000-03-17 WO PCT/US2000/007202 patent/WO2000056317A1/en not_active Application Discontinuation
- 2000-03-17 AU AU41729/00A patent/AU4172900A/en not_active Abandoned
- 2000-03-17 MX MXPA01009465A patent/MXPA01009465A/en unknown
- 2000-03-17 TR TR2001/02694T patent/TR200102694T2/en unknown
- 2000-03-17 CA CA002367268A patent/CA2367268A1/en not_active Abandoned
- 2000-03-17 CN CN00807535A patent/CN1352553A/en active Pending
- 2000-03-17 IL IL14524300A patent/IL145243A0/en unknown
- 2000-03-17 CZ CZ20013282A patent/CZ20013282A3/en unknown
- 2000-03-17 KR KR1020017011956A patent/KR20010113848A/en not_active Application Discontinuation
-
2001
- 2001-09-14 NO NO20014474A patent/NO20014474L/en unknown
- 2001-09-18 ZA ZA200107680A patent/ZA200107680B/en unknown
- 2001-10-10 BG BG105995A patent/BG105995A/en unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0200500A2 (en) | 2002-08-28 |
CZ20013282A3 (en) | 2002-07-17 |
AU4172900A (en) | 2000-10-09 |
WO2000056317A1 (en) | 2000-09-28 |
SK13362001A3 (en) | 2002-07-02 |
JP2002539253A (en) | 2002-11-19 |
KR20010113848A (en) | 2001-12-28 |
BG105995A (en) | 2002-06-28 |
IL145243A0 (en) | 2002-06-30 |
EP1162966A1 (en) | 2001-12-19 |
EP1162966A4 (en) | 2002-06-12 |
BR0009078A (en) | 2001-12-26 |
TR200102694T2 (en) | 2002-04-22 |
NZ514015A (en) | 2001-09-28 |
PL351080A1 (en) | 2003-03-10 |
NO20014474D0 (en) | 2001-09-14 |
ZA200107680B (en) | 2003-06-18 |
CA2367268A1 (en) | 2000-09-28 |
MXPA01009465A (en) | 2004-03-19 |
NO20014474L (en) | 2001-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1188120C (en) | Method for treating eating disorders | |
CN1070698C (en) | medical treatment | |
KR20010033531A (en) | Therapeutic Agents | |
US6376553B1 (en) | Treatment of pain | |
CN1161114C (en) | Method of treating sleep apnoea | |
US6376552B1 (en) | Treatment of gallstones | |
WO2000056318A1 (en) | Treatment of neuropathic pain or fibromyalgia | |
WO2000056149A1 (en) | Method of treating anxiety disorders | |
WO2000056310A1 (en) | Treatment of chronic fatigue syndrome | |
WO2000056320A1 (en) | Treatment of menstrual function | |
CN1352553A (en) | Weight loss after pregnancy | |
CN1399545A (en) | Treatment of certain cancers associated with weight gain | |
CN1352552A (en) | Treatment of osteoarthritis | |
WO2000056148A1 (en) | Treatment of pharmacology of drug misuse and other addictive disorders | |
US6403650B1 (en) | Treatment of pulmonary hypertension | |
US20040198837A1 (en) | Treatment of neuropathic pain or fibromyalgia | |
WO2000056322A1 (en) | Treatment to lower platelet adhesiveness | |
CN1376061A (en) | Treatment of hiatial hernia | |
US20030008897A1 (en) | Method of controlling weight gain associated with therapeutic drugs | |
WO2000056151A1 (en) | Method of treating obsessive-compulsive disorder | |
WO2000056319A1 (en) | Treatment of orthostatic hypotension | |
US20020132856A1 (en) | Treatment of premenstrual syndrome | |
EP1165060A1 (en) | Treatment of gallstones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |